Growth Hormone for Poor Responders in in Vitro Fertilization (IVF)
Launched by OTTAWA FERTILITY CENTRE · Sep 16, 2010
Trial Information
Current as of June 10, 2025
Completed
Keywords
ClinConnect Summary
Growth hormone (GH; Saizen®) is indicated for the treatment of growth hormone deficiency in both children and adults, as well as for Turner's Syndrome, chronic renal failure, and children born short for gestational age.
In animal studies, growth hormone has been shown to be important in early antral follicle recruitment, subsequent follicular growth, and oocyte maturation. Together with insulin-like growth factor-1 (IGF-1), growth hormone is essential early on in the recruitment of primordial follicles in the growing pool (Slot et al 2006, Wandji et al 1992, Donadeu \& Peterson 2008, Scara...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • less than 42 years of age
- • previous IVF cycle with high doses of gonadotropins (defined as greater than or equal to 400 IU/day)
- • produced less than 6 follicles greater than or equal to 15mm
- Exclusion Criteria:
- • any known contraindications to the approved fertility drugs as per the Canadian Product Monographs
- • any contraindications to growth hormone, pregnancy (to be ruled out and documented before GH treatment), or are at risk for gestational diabetes
About Ottawa Fertility Centre
The Ottawa Fertility Centre (OFC) is a leading reproductive health clinic dedicated to providing comprehensive fertility services and innovative treatment options. With a commitment to advancing reproductive medicine, OFC conducts clinical trials aimed at improving patient outcomes and exploring novel approaches to fertility challenges. The center is staffed by a multidisciplinary team of highly trained specialists who leverage state-of-the-art technology and evidence-based practices to deliver personalized care tailored to each patient's unique needs. Through its research initiatives, the Ottawa Fertility Centre strives to contribute to the global understanding of fertility and enhance the quality of care for individuals and couples facing reproductive challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ottawa, Ontario, Canada
Patients applied
Trial Officials
Arthur Leader, BSc., MD, FRCSC
Principal Investigator
Ottawa Fertility Centre
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials